Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation

NCT05318976 is registered in ClinicalTrials.gov with Inmune Bio, Inc. as lead sponsor.

NCT NCT05318976
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05318976 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation
Lead sponsor
Inmune Bio, Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2022
Completion date
May 12, 2025
Enrollment
207 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, brain diseases, central nervous system diseases, dementia, mental disorders, mild cognitive impairment, nervous system diseases, neurocognitive disorders, neurodegenerative diseases, tauopathies